Metabolic & Cardiometabolic
galacto-oligosaccharides improves insulin sensitivity
In plain terms: Does the prebiotic fiber GOS help control blood sugar?
Unsettled. The best-designed trial, in obese prediabetics, found GOS shifts gut bacteria (more bifidobacteria) without improving insulin sensitivity, energy metabolism or plasma metabolites; other studies disagree, which is why this is contested rather than refuted.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
GOS robustly raises bifidobacteria; whether it improves insulin sensitivity is contested — the best-designed trial, in obese prediabetics, found no improvement in insulin sensitivity, energy metabolism or plasma metabolites, while other studies disagree. A microbiome-claim ingredient first; a metabolic one not yet.
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Stachowska E, Portincasa P, Jamioł-Milc D, Maciejewska-Markiewicz D, Skonieczna-Żydecka K 2020 · Nutrients | observational | tested-null | low | SR of prebiotic fibre (incl GOS) in NAFLD: favorable reductions in HOMA-IR, fasting insulin and BMI vs control |
| Hosseini E, Mokhtari Z, Askari G 2025 · J Nutr | meta-analysis | mixed | low | SR/MA prebiotics in prediabetes: body-fat reduction suggests insulin-sensitivity potential but very low certainty for glycemic outcomes |
| Krumbeck JA, Rasmussen HE, Hutkins RW, Clarke J, Shawron K, Keshavarzian A, Walter J 2018 · Microbiome | RCT | tested-null | moderate | Bifidobacterium+GOS synbiotic showed no functional metabolic synergy; GOS alone improved gut-barrier markers but did not demonstrate insulin-sensitivity benefit |
| He N, Chen H, Zhou Z, Zhao W, Wang S, Lv Z, Liu N, Wang H, Yang Z, Li S 2021 · Food Funct | animal | supports | moderate | Enzymatically synthesized alpha-GOS reversed HFD-induced metabolic syndrome incl insulin resistance and inflammation via gut-microbiota modulation in mice |
| Vulevic J, Juric A, Tzortzis G, Gibson GR 2013 · J Nutr | RCT | supports | moderate | B-GOS reduced fasting insulin, TC and TG in overweight adults |
| Li Y, Kong H, Li C, Gu Z, Ban X, Li Z 2024 · Food & function | animal | contradicts | moderate | High-fat-diet mice given XOS, GOS, or IMO: GOS significantly altered gut microbiota composition but did not enhance insulin sensitivity, whereas IMO specifically enhanced insulin sensitivity via the PI3K/Akt pathway. XOS+IMO combination (no |
| Canfora EE, van der Beek CM, Hermes GDA, Goossens GH, Jocken JWE, Holst JJ, van Eijk HM, Venema K, Smidt H, Zoetendal EG, Dejong CHC, Lenaerts K, Blaak EE 2017 · Gastroenterology | RCT | contradicts | high | Double-blind placebo-controlled RCT, n=44 overweight/obese prediabetics, 15 g/d GOS vs maltodextrin for 12 weeks; primary outcome peripheral insulin sensitivity by hyperinsulinemic-euglycemic clamp: 'no significant alterations in peripheral and adipose tissue insulin sensitivity, body composition, and energy and substrate metabolism were found', despite a 5-fold fecal Bifidobacterium rise (P = .009; q = 0.144). Null on the claim's object in its scoped population, so contradicts; no estimate or CI given in the abstract. |
| Vulevic J, Juric A, Walton GE, Claus SP, Tzortzis G, Toward RE, Gibson GR 2015 · Br J Nutr | RCT | mixed | moderate | B-GOS shifted microbiota/immune markers but no insulin-sensitivity improvement |
| Beteri B, Barone M, Turroni S, Brigidi P, Tzortzis G, Vulevic J, Sekulic K, Motei DE, Costabile A 2024 · Nutrients | RCT | mixed | low | 12wk GOS+postbiotic fibre supplement in prediabetes lowered HbA1c and fasting plasma glucose below prediabetes thresholds vs no change in placebo |
| Zhang C, Zhang Q, Zhang X, Du S, Zhang Y, Wang X, Liu Y, Fang B, Chen J, Liu R, Hao Y, Li Y, Wang P, Zhao L, Feng H, Zhu L, Chen L, Chen S, Wang F, Jiang Z, Ji Y, Xiao R, Wang R, He J 2024 · Clin Nutr | RCT | supports | moderate | Synbiotic containing GOS reduced fasting blood glucose in T2DM beyond probiotic alone, with enhanced GLP-1 secretion and Bifidobacterium correlated to glycemia |
| Gonai M, Shigehisa A, Kigawa I, Kurasaki K, Chonan O, Matsuki T, Yoshida Y, Aida M, Hamano K, Terauchi Y 2017 · Benef Microbes | RCT | contradicts | moderate | GOS restored Bifidobacteriaceae but did not improve glucose tolerance or glycemic control in type 2 diabetics over the trial. |
| Mistry RH, Liu F, Borewicz K, Lohuis MAM, Smidt H, Verkade HJ, Tietge UJF 2020 · Mol Nutr Food Res | animal | supports | moderate | Long-term beta-GOS in Western-diet mice improved body weight gain, dyslipidemia and insulin sensitivity with higher intestinal GLP-1 expression |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.